An Open Label Long-term Extension study to investigate the safety of PF-06823859 Administered to Adult Participants with Active Dermatomyositis (C0251008)

Brief description of study

The purpose of this study (C0251008) is to evaluate the long-term safety, and effectiveness of PF06823859 (active study drug) in adult participants with dermatomyositis (DM) from a qualifying study (such as the C0251002 study). The C0251008 study was established to allow participants who were participating in a qualifying study to continue on active treatment for an additional 48 weeks. All participants entering the C0251008 study will receive active study drug treatment, 600 mg IV every 4 weeks. At week 52, participants will enter into a follow up period of 16 weeks. Overall, the C0251008 study will be 68 weeks duration, with visits occurring every 4 weeks.

Clinical Study Identifier: s21-01421 Identifier: NCT05192200
Principal Investigator: Alisa N Femia.
Other Investigator: Kristen Lo Sicco.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.